Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Reiner

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry|October 25, 2021
Histamine H<sub>3</sub> receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisationMarkus Falkenstein, David Reiner-Link, Aleksandra Zivkovic, et al.
Chemical Biology & Drug Design|December 27, 2018
Histamine H<sub>3</sub> receptor ligands by hybrid virtual screening, docking, molecular dynamics simulations, and investigation of their biological effectsNakisa Ghamari, Omid Zarei, David Reiner, et al.
British Journal of Pharmacology|May 10, 2024
Differential G protein activation by the long and short isoforms of the dopamine D<sub>2</sub> receptorDavid Reiner-Link, Jakob Sture Madsen, David E Gloriam, et al.
Plos One|July 18, 2015
Time-Dependent Protection of CB2 Receptor Agonist in StrokeSeong-Jin Yu, David Reiner, Hui Shen, et al.
Pharmacology & Therapeutics|April 28, 2019
Histamine H<sub>3</sub> receptor antagonists/inverse agonists: Where do they go?Nakisa Ghamari, Omid Zarei, José-Antonio Arias-Montaño, et al.
Molecules (Basel, Switzerland)|April 30, 2021
Discovery of Potential, Dual-Active Histamine H<sub>3</sub> Receptor Ligands with Combined Antioxidant PropertiesKamil J Kuder, Magdalena Kotańska, Katarzyna Szczepańska, et al.
Neuropharmacology|June 24, 2022
OLHA (N<sup>α</sup>-oleoylhistamine) modulates activity of mouse brain histaminergic neuronsOlga A Sergeeva, Karolina Mazur, David Reiner-Link, et al.
Plos Genetics|November 19, 2016
CDC-42 Orients Cell Migration during Epithelial Intercalation in the Caenorhabditis elegans EpidermisElise Walck-Shannon, Bethany Lucas, Ian Chin-Sang, et al.
International Journal of Molecular Sciences|March 6, 2021
The Multi-Targeting Ligand ST-2223 with Histamine H<sub>3</sub> Receptor and Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Antagonist Properties Mitigates Autism-Like Repetitive Behaviors and Brain Oxidative Stress in MiceNermin Eissa, Karthikkumar Venkatachalam, Petrilla Jayaprakash, et al.
Bioorganic & Medicinal Chemistry|December 21, 2022
Multitargeting approaches to cognitive impairment: Synthesis of aryl-alkylpiperazines and assessment at cholinesterases, histamine H<sub>3</sub> and dopamine D<sub>3</sub> receptorsCecília M S Q Aranha, David Reiner-Link, Luisa R Leitzbach, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry|October 25, 2021
Histamine H<sub>3</sub> receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisationMarkus Falkenstein, David Reiner-Link, Aleksandra Zivkovic, et al.
Chemical Biology & Drug Design|December 27, 2018
Histamine H<sub>3</sub> receptor ligands by hybrid virtual screening, docking, molecular dynamics simulations, and investigation of their biological effectsNakisa Ghamari, Omid Zarei, David Reiner, et al.
British Journal of Pharmacology|May 10, 2024
Differential G protein activation by the long and short isoforms of the dopamine D<sub>2</sub> receptorDavid Reiner-Link, Jakob Sture Madsen, David E Gloriam, et al.
Plos One|July 18, 2015
Time-Dependent Protection of CB2 Receptor Agonist in StrokeSeong-Jin Yu, David Reiner, Hui Shen, et al.
Pharmacology & Therapeutics|April 28, 2019
Histamine H<sub>3</sub> receptor antagonists/inverse agonists: Where do they go?Nakisa Ghamari, Omid Zarei, José-Antonio Arias-Montaño, et al.
Molecules (Basel, Switzerland)|April 30, 2021
Discovery of Potential, Dual-Active Histamine H<sub>3</sub> Receptor Ligands with Combined Antioxidant PropertiesKamil J Kuder, Magdalena Kotańska, Katarzyna Szczepańska, et al.
Neuropharmacology|June 24, 2022
OLHA (N<sup>α</sup>-oleoylhistamine) modulates activity of mouse brain histaminergic neuronsOlga A Sergeeva, Karolina Mazur, David Reiner-Link, et al.
Plos Genetics|November 19, 2016
CDC-42 Orients Cell Migration during Epithelial Intercalation in the Caenorhabditis elegans EpidermisElise Walck-Shannon, Bethany Lucas, Ian Chin-Sang, et al.
International Journal of Molecular Sciences|March 6, 2021
The Multi-Targeting Ligand ST-2223 with Histamine H<sub>3</sub> Receptor and Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Antagonist Properties Mitigates Autism-Like Repetitive Behaviors and Brain Oxidative Stress in MiceNermin Eissa, Karthikkumar Venkatachalam, Petrilla Jayaprakash, et al.
Bioorganic & Medicinal Chemistry|December 21, 2022
Multitargeting approaches to cognitive impairment: Synthesis of aryl-alkylpiperazines and assessment at cholinesterases, histamine H<sub>3</sub> and dopamine D<sub>3</sub> receptorsCecília M S Q Aranha, David Reiner-Link, Luisa R Leitzbach, et al.
Pageof 4